Projekt

Merck EORTC 1325 / MK-3475-054 - Adjuvant immunotherapy with anti-PD-1 monoclonal anti-body Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage III melanoma: A ran-domized, double- blind Phase 3 trial of the EORTC Mela-noma Group

Automatisch geschlossen · 2016 bis 2020

Fehr Martin